BTG has announced a strategic partnership with the PERT Consortium to advance the science of pulmonary embolism treatment and promote the implementation of PERT programmes across the USA. The partnership was announced at the annual PERT Consortium Meeting (22–23 June, Nashville, USA).
In the USA, pulmonary embolism afflicts 500,000–600,000 patients annually and is either a primary or secondary cause of death in 150,000–200,000 of these individuals. In their new partnership, BTG and the PERT Consortium are uniting to address this disease via expanding options for professional education, expanding clinical research, establishing quality benchmarks for care of pulmonary embolism, and developing new mobile technologies to convene PERT teams and improve decision-making.
“With this partnership, we are reaffirming our long-standing commitment to improving patient care and reducing in-hospital mortality associated with pulmonary embolism,” says BTG chief medical officer, Francis Facchini. “By partnering with the PERT Consortium, we hope to develop new strategies to transform the pulmonary embolism treatment paradigm.”
“We applaud BTG’s commitment to research and their leadership in the field of pulmonary embolism,” says PERT Consortium president, Victor Tapson. “This partnership will expand the body of clinical evidence and improve multidisciplinary decision-making for pulmonary embolism patients.”
“Pulmonary embolism is a pervasive disease that is under-recognised and undertreated,” according to Consortium Immediate Past-president, Kenneth Rosenfield. “Our collaboration with BTG will enable the PERT Consortium to increase provider and patient awareness about pulmonary embolism, and establish new benchmarks for high quality care of the patient with this disease.”
About Pulmonary Embolism Response Teams (PERT)
The first PERT was created by a multi-disciplinary team of physicians at Massachusetts General Hospital (MGH) in 2012. Their intent was to develop the necessary clinical, educational, and research infrastructure for the advancement of pulmonary embolism care. Since then, the PERT multidisciplinary approach has allowed for the streamlined evaluation of patients, formulation of comprehensive treatment plans and the rapid mobilisation of resources to provide the highest level of care to those in need. The PERT model has since grown in popularity and continues to be adopted by institutions across the USA and beyond.
About the PERT Consortium
The PERT Consortium is a not-for-profit 501c3 organisation, whose mission is to serve the general public by undertaking activities to advance the status of PE care and promote research, enhance quality, and optimise outcome in the treatment of pulmonary embolism. Specifically, the Consortium intends to: 1) Promote the adoption of the PERT model in healthcare institutions across the USA to ensure the prompt diagnosis and high quality treatment of pulmonary embolism; 2) Expand the current body of scientific literature on the diagnosis and treatment of pulmonary embolism through the funding of scientific endeavours; 3) Educate the general public and healthcare professionals regarding pulmonary embolism diagnosis, treatment, and care.
